z-logo
open-access-imgOpen Access
PET imaging of Hsp90 expression in pancreatic cancer using a new 64Cu-labeled dimeric Sansalvamide A decapeptide
Author(s) -
Xiaohui Wang,
Jun Zhang,
Hubing Wu,
Yumin Li,
Peter S. Conti,
Kai Chen
Publication year - 2018
Publication title -
amino acids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.894
H-Index - 118
eISSN - 1438-2199
pISSN - 0939-4451
DOI - 10.1007/s00726-018-2566-y
Subject(s) - hsp90 inhibitor , biodistribution , in vivo , pancreatic cancer , ex vivo , pancreas , positron emission tomography , heat shock protein , cancer , hsp90 , chemistry , cancer research , imaging agent , in vitro , pathology , microbiology and biotechnology , medicine , nuclear medicine , biochemistry , biology , gene
Heat shock protein 90 (Hsp90) plays a vital role in the progress of malignant disease and elevated Hsp90 expression has been reported in pancreatic cancer. In this study, we radiolabeled a dimeric Sansalvamide A derivative (Di-San A1) with 64 Cu, and evaluated the feasibility of using 64 Cu-Di-San A1 for PET imaging of Hsp90 expression in a mouse model of pancreatic cancer. A macrocyclic chelator NOTA (1,4,7-triazacyclononane-1,4,7-trisacetic acid) was conjugated to Di-San A1. 64 Cu-Di-San A1 was successfully prepared in a radiochemical yield > 97% with a radiochemical purity > 98%. 64 Cu-Di-San A1 is stable in PBS and mouse serum with > 92% of parent probe intact after 4 h incubation. The cell binding and uptake revealed that 64 Cu-Di-San A1 binds to Hsp90-positive PL45 pancreatic cancer cells, and the binding can be effectively blocked by an Hsp90 inhibitor (17AAG). For microPET study, 64 Cu-Di-San A1 shows good in vivo performance in terms of tumor uptake in nude mice bearing PL45 tumors. The Hsp90-specific tumor activity accumulation of 64 Cu-Di-San A1 was further demonstrated by significant reduction of PL45 tumor uptake with a pre-injected blocking dose of 17AAG. The ex vivo PET imaging and biodistribution results were consistent with the quantitative analysis of PET imaging, demonstrating good tumor-to-muscle ratio (5.35 ± 0.46) of 64 Cu-Di-San A1 at 4 h post-injection in PL45 tumor mouse xenografts. 64 Cu-Di-San A1 allows PET imaging of Hsp90 expression in PL45 tumors, which may provide a non-invasive method to quantitatively characterize Hsp90 expression in pancreatic cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here